NLY01, a GLP-1 receptor agonist, could inhibit the conversion of pro-inflammatory astrocytes induced by microglia in a mouse PD model [155] and is tested in a phase II trial in patients with early PD (NCT04154072) [284]. Here, GLP1R is linked to Parkinson disease.